Navigation Links
ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
Date:7/24/2012

EXTON, Pa., July 24, 2012 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2012 are expected to be released no later than Thursday, August 9, 2012.  In light of the August 9th PDUFA date for industrial scale expansion of Cinryze® (C1 esterase inhibitor [human]), the company has chosen to align the two events. In the event the company receives a response from the FDA prior to August 9th, the company will announce the specific timing of the conference call upon receipt of the FDA response.

During the conference call, ViroPharma management will discuss the 2012 second quarter financial results and other business including the FDA decision regarding industrial scale expansion of Cinryze.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until August 23, 2012.  To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call. 

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standar
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
2. ViroPharma To Participate In The JMP Securities Healthcare Conference
3. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
4. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
5. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
6. Top 100 Drug Sales Data Released - Plavix Leads the Way
7. Berkery Noyes Releases First Half 2012 M&A Report For the Healthcare/Pharma Information and Technology Industry
8. Medica Announces Global Release of the EasyCell Assistant Analyzer for Hematology Laboratories
9. Merit Medical Systems Announces Earnings Release Date/Time And Conference Call Information For The Second Quarter Ended June 30, 2012
10. Span-America Medical Systems To Release Third Quarter Results On August 2, 2012
11. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "MEMS Gyroscopes Analog Devices ADIS16136 Precision ... to their offering. ... grade applications made a lot of progress in ... They are now accepted in high-reliability environments, and ...
(Date:12/15/2014)... 2014 BerGenBio AS, a biopharmaceutical ... resistant cancers, today announces that it has raised NOK90 ... new and existing investors. BerGenBio will use ... of its pipeline of innovative cancer therapeutics, in particular ... candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... of Directors.  Dr. McKinnell is the former Chief Executive ... of Pfizer Inc.  He is currently Chairman of the ... infectious diseases in Africa, and is a member of ...
... and NEW YORK, Jan. 10, 2011 Resolvyx Pharmaceuticals ... Celtic Therapeutics ), a successor firm to Celtic Pharma, ... agreement under which Celtic Therapeutics has acquired and licensed ... for the treatment of dry eye syndrome and other ...
Cached Medicine Technology:Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 2Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 3Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors 4Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 2Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 3Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology 4
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a new weight ... co-founder of the Ace Medical Weight Loss Center in Rock ... look at the industry of weight loss, and how several ... and in television shows, however, she says the topic of ... played for basic laughs, which she believes impacts whether Americans ...
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
(Date:12/17/2014)... 16, 2014 (HealthDay News) -- Poor students get more fruits ... new study finds. But, the opposite is true for ... fruits and vegetables at school may give a healthy boost ... no matter what the family income level, students all ate ... study found. The study was published recently in the ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... depression resulting form multiple sclerosis had showed marked ... // The results of the investigation were reported ... Psychiatry. ,Although two-thirds of depressed patients prefer ... ever make a first appointment and nearly half ...
... the spread of gastrointestinal infections in the home. // ... families, which used the hand sanitizer in gel form, ... illness related to the gastrointestinal tract. ,Families ... Half the families were randomly assigned to receive hand ...
... high regard since the very old days and it continues ... recreation forms have been able to substitute mankind with another ... sudden death associated with exercise in young competitors. The benefits ... ,Recent medical research has reported that adolescents and ...
... elevate the role of fibres further by stating that ... plaque build-up in the arteries in postmenopausal women.// ... with a decreased risk of heart disease and death. ... fruit, and vegetables, and refined grain products on the ...
... said that the government would include Hepatitis B ... has been emerging as a "problem greater than ... Indian Council of Medical Research (ICMR)-World Health Organisation ... leptospirosis at the regional ICMR centre here, the ...
... Manoor Prakash Hande and his colleagues from National University ... risk of developing Chromosomal aberrations leading to cancer// in ... aimed at identifying biomarkers for easy detection and identification ... finding a link between complex chromosome aberrations and disease ...
Cached Medicine News:Health News:MS Patients Improve With Telephone Therapy 2Health News:Alcohol based sanitizer found to reduce illness in families 2Health News:Competitive Sports: Is the heart Sportive Enough? 2
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States....
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
... Hi-Mag takes us to the practical ... magnifier is often a 'last resort' ... visual acuities. The illuminated housing ensures ... to the battery handle by a ...
Medicine Products: